Delivery Order SPE2DB22D3011-SPE2DB24FP8LJ

Award Date 1/5/24
Potential Completion Date 1/8/24
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was made to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ondansetron ODT 8 mg tablets. The $11,254.23 fixed-price Delivery Order contract has a completion date of May 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,517.18 firm fixed-price delivery order is for the supply of 4,566,249,434 units of ondansetron ODT 8 mg tablets. The contract has an ultimate completion date of October 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of ondansetron ODT 4 mg tablets. The contract is a delivery order with a firm fixed price of $17,942.55 and a period of performance through March 4, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as the primary vehicle for supplying a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ondansetron ODT 4 mg tablets. The $7,500.96 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical. This IDC serves as a comprehensive contracting vehicle for the company to supply a wide range of pharmaceutical products and medical supplies,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,695.23, is for the delivery of Ondansetron ODT 4 mg tablets. This is a firm-fixed-price delivery order contract with a completion date of January 23, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ondansetron ODT 4 mg tablets. The fixed-price, delivery order contract has a ceiling value of $1,320.33 and an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,893.58, is a delivery order for the supply of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of November 22, 2024 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,707.55 firm fixed price delivery order is for the supply of 4,566,197,426 units of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of October 25, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a large pharmaceutical distributor, for the delivery of 4,566,740,595 units of the medication Ondansetron ODT 4 mg tablet. The award, valued at $1,316.14, is a firm fixed-price delivery order with a completion date of December 18, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,327.73 Firm Fixed Price Delivery Order is for the supply of 4,564,802,515 units of Ondansetron ODT 4 mg Tablets. The contract has an ultimate completion date of June 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FP8LJ
    Delivery Order

This federal contract award was granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ondansetron ODT 4 mg tablets. The contract, valued at $10,838.21, is a firm fixed-price delivery order with a completion date of January 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 5/13/25, 9:50 AM